PT-141 (Bremelanotide)
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It acts centrally via MC3R and MC4R in the hypothalamus to modulate sexual arousal pathways independent of vascular mechanisms, distinguishing it from PDE5 inhibitors.
Acute effect, typically within a few hours of dosing.
Topical and cosmetic formulations: store per the product directions, typically cool and away from light; follow any beyond-use date.
Clinical Evidence
What the literature says
Scientific Overview
Bremelanotide (Vyleesi) is FDA-approved for premenopausal HSDD. Acts on MC4R in the hypothalamus.
Pharmacokinetics
- Half-life (t½)
- 2.7 h
- Approximate plasma half-life
- Routes
- Subcutaneous
Citations (7)
- Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment OptionsPubMed 2026
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionPubMed
- PT-141: a melanocortin agonist for the treatment of sexual dysfunctionPubMed
- An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonistPubMed
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal womenPubMed
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsReview
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderReview
Last reviewed: 2026-05-09
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesOn-Demand
“Max 1 dose/24h, 8 doses/month”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi)
- Studied for male sexual dysfunction in early-stage clinical trials
- Investigated for appetite regulation via central melanocortin signaling
Key Research Benefits
- Increases libido
- Acts on CNS, not vascular
- Works in both sexes
Potential Side Effects
Considerations and Cautions
- Contraindicated with cardiovascular disease or uncontrolled hypertension
- Transient blood pressure increases reported post-dose; require 2 hours monitoring at first use
- Not approved for use in men or postmenopausal women outside clinical trials
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- No validated compound-specific markers: No standard bloodwork is established for this compound; general safety labs (CBC, comprehensive metabolic panel) are reasonable if used under medical supervision.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.40 mL on a U-100 syringe
PT-141 (Bremelanotide) by goal
Read PT-141 (Bremelanotide)'s profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.